Drug intelligence / Profile preview

GC01solution

Development stage: Preclinical
Lead developer: GlioCure
Modality: Peptides
Administration: Intratumoral

Overview

GC01solution is a synthetic peptide therapeutic being developed by GlioCure for the treatment of non-resectable glioblastoma and other solid tumors. The drug specifically targets βIII-tubulin (tubulin beta-3 chain), a microtubule component that is highly expressed in aggressive, drug-resistant cancer cells but absent in healthy mature neurons. GC01 exhibits a dual mechanism of action, providing both anti-tumor activity by inhibiting tumor cell proliferation and neuroprotective effects to preserve healthy brain tissue. The solution formulation is designed for local administration to address tumors that are not amenable to surgical resection. It is currently in the lead optimization and preclinical stage of development.

Other names: GC01GC-01GC 01GC01.1GC-01.1GC 01.1

Targets

TUBB3 (Tubulin beta-3 chain)

Beyond the preview

Go deeper on GC01solution.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC01solution.

Explore the full profile